{
  "meta": {
    "timestamp": "2025-01-06T07:50:32.760544",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Natera Inc",
      "symbol": "NTRA",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Reimbursement challenges impacting revenue and profitability",
            "Regulatory and legal risks, including patent infringement lawsuits and a $292.5 million false advertising verdict",
            "High competition in the genetic testing market",
            "Data privacy concerns related to handling sensitive genetic data",
            "Valuation concerns with potential for a stock pullback"
          ],
          "controversies": [
            "Multiple patent infringement lawsuits, including a high-profile case against NeoGenomics",
            "$292.5 million verdict in a false advertising lawsuit with Guardant Health"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Data privacy concerns and potential breaches affecting patient trust"
          ],
          "governance_issues": [
            "Regulatory scrutiny and compliance risks",
            "Litigation risks impacting financial stability"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Women's Health Pricing & Billing | Natera",
              "snippet": "1 Natera may attempt to contact patients via email or text. Patients should monitor their emails, texts, and spam folders for communication from Natera. 2 Natera's patient out-of-pocket cost estimates are based on the information we have available to us at the time of the estimate. Future or pending claims submitted to your insurance may ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.761950+00:00",
              "published_date": null,
              "source_hash": "1564f96726459b05027736d37cb73e0f"
            },
            {
              "url": "",
              "title": "Natera at JP Morgan: Big Lessons on Reimbursement Strength",
              "snippet": "The chart above, used by Natera at JPM, shows year-on-year growth in Q4 revenue alone - from $67M in 2018, to $300M in 2023. They highlight average sales price - a reimbursement issues - as a key driver. Not shown here, Natera's bar chart for test volumes looks similar - from 670K in 2014 to 2,490K in 2023.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762144+00:00",
              "published_date": null,
              "source_hash": "a2444c75a0e14ae00a881d3718c82ecb"
            },
            {
              "url": "",
              "title": "Update: Natera genetic testing and large insurance explanation of ...",
              "snippet": "Talk to your drs office. My dr said it would be $200 flat through Natera if going through my insurance was over $200 and said Natera would call me if that was the case. They didn't call, went through my insurance and I owed $500. Talked to my dr who gave me a contact at Natera who quickly changed the fee to the quoted $200.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762175+00:00",
              "published_date": null,
              "source_hash": "c8daecbc9a3581b8c19395d9052bbdab"
            },
            {
              "url": "",
              "title": "Signatera and Altera Insurance Coverage and Billing",
              "snippet": "Signatera and Altera Insurance Coverage and Billing; Signatera and Altera Insurance Coverage and Billing The first personalized ctDNA test to identify molecular residual disease and optimize treatment decisions. Read our billing guide for information about understanding Natera's genetic testing bill. ... CAP accredited, ISO 13485 certified, and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762188+00:00",
              "published_date": null,
              "source_hash": "9cc6f579a8b7bb0cfe0f95c267b708c0"
            },
            {
              "url": "",
              "title": "Natera claim denied by insurance : r/pregnant - Reddit",
              "snippet": "Yea my insurance denied the $7,000 bill for Natera. Natera sent me a bill for $250 like 8 months later. But I didn't see it as I had just had the baby. So 60 days later they sent a bill for $250 + $100 late fee. I called them and after being on the phone for 30 minutes, they reversed the $100 late fee. ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762200+00:00",
              "published_date": null,
              "source_hash": "9dd579fda4a11da71b5ba669b2d16e78"
            },
            {
              "url": "",
              "title": "Class Action Alleges Customers Received Surprise Bills for Natera ...",
              "snippet": "Natera, Inc. faces a proposed class action that claims the genetic testing company has misrepresented the costs of its tests and hit thousands of patients with unexpected, \"extremely high\" bills. ... although Natera represents that it will provide insurance estimates and contact patients to determine how they want to pay in the event their ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762210+00:00",
              "published_date": null,
              "source_hash": "a0876a167a7115df80868b62df33f892"
            },
            {
              "url": "",
              "title": "Signatera Billing | Natera",
              "snippet": "We welcome all insurance plans** We will work with patients so that cost is not a barrier for testing; We offer an affordable cash pay rate for those patients who do not wish to use insurance (exclusions may apply) For additional questions regarding cost, Natera's billing phone number is 650-489-9050. Please select 2 for patients. Select 4 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762219+00:00",
              "published_date": null,
              "source_hash": "0fd55ca8729bd919629ab6c044051f8e"
            },
            {
              "url": "",
              "title": "California Genetic Testing Service Pays $11 Million To Resolve False ...",
              "snippet": "Allegedly submitted fraudulent medical claims for reimbursement. Will Pay $10,635,615.90 as part of Federal Settlement and $756,183 to a Number of States. LOUISVILLE, Ky. ... Inc., to resolve claims that Natera improperly billed federal healthcare programs for Natera's non-invasive prenatal test known as Panorama ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762230+00:00",
              "published_date": null,
              "source_hash": "371c06a5f177f61af5194d065a48f9de"
            },
            {
              "url": "",
              "title": " Natera, Inc. - Seeking Alpha",
              "snippet": "this presentation, including statements regarding the market opportunity, products and launch schedules, reimbursement covera ge and product costs, commercial partners, user experience, clinical trials, financial performance, strategies, anticipated revenue and financial outlook and goals and general business condition s of Natera, Inc ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762239+00:00",
              "published_date": null,
              "source_hash": "4120fa8139b373da73bbc80e290281a5"
            },
            {
              "url": "",
              "title": "Natera: Pioneers In Deceptive Medical Billing - Hindenburg Research",
              "snippet": "Natera Inc. is an Austin-based genetic testing company providing DNA screening services. Its core product business is largely in women's health and non-invasive prenatal testing (NIPT), which comprised approximately 91% of the company's 2021 revenue. ... the two codes allow Natera to seek reimbursement for the 2 tests separately and bill ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:00.762248+00:00",
              "published_date": null,
              "source_hash": "886ac27c6473267c25f5c2f83fab2fb3"
            },
            {
              "url": "",
              "title": "Natera Announces Medicare Coverage for Prospera\u2122 in Single Lung Transplant Recipients",
              "snippet": "AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Prospera Lung test has met coverage requirements from ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:04.373514+00:00",
              "published_date": "2024-11-27T09:00:00+00:00",
              "source_hash": "06ef89143836ee4a99b5c75f27f70a36"
            },
            {
              "url": "",
              "title": "Guardant Health gains amid $292.5M verdict against Natera over false advertising claims (update)",
              "snippet": "Guardant Health (NASDAQ:GH) rose 8.4% at least partly after a North California jury awarded the company $292.5 million in a false advertising lawsuit against Natera (NTRA) over Guardant's Reveal ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:04.373612+00:00",
              "published_date": "2024-11-25T20:54:00+00:00",
              "source_hash": "206a4c5c4eb8f7616a07320df0aafafd"
            },
            {
              "url": "",
              "title": "Natera, Inc. (NASDAQ:NTRA) Shares Purchased by Captrust Financial Advisors",
              "snippet": "Natera, Inc. has a 1 year low of $55.56 and a 1 year high of $175.63. The stock has a 50-day simple moving average of $141.76 and a 200-day simple moving average of $123.46.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:04.373628+00:00",
              "published_date": "2024-12-11T00:00:00+00:00",
              "source_hash": "19dd7cc712aa16cbcc2a2d362d93c156"
            },
            {
              "url": "",
              "title": "Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%",
              "snippet": "Billionaire Stanley Druckenmiller's latest large wager on biotech company Natera Inc has paid off, with his stake now exceeding $575 million.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc reimbursement challenges insurance",
              "retrieved_at": "2025-01-06T14:50:04.373649+00:00",
              "published_date": "2024-12-20T18:26:00+00:00",
              "source_hash": "64252867d99eb50ae5d20e1dcc728ba3"
            },
            {
              "url": "",
              "title": "Natera, Inc. | Court Grants Natera's Request to Include Additional ...",
              "snippet": "Amended complaint asserts infringement of U.S. Patent Nos. '596 and '454 by the modified version of NeoGenomics' RaDaR assay Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR\u00ae tests. On December 10, 2024, the District Court for the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941644+00:00",
              "published_date": null,
              "source_hash": "a654d01ccdd9e5ad711bfdfa37c2740b"
            },
            {
              "url": "",
              "title": "Court Grants Natera's Request to Include Additional Patent in its ...",
              "snippet": "AUSTIN, Texas-(BUSINESS WIRE)- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR\u00ae tests. On December 10, 2024, the District Court for the Middle District of North Carolina (\"The District Court\") granted Natera's request to include an ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941629+00:00",
              "published_date": null,
              "source_hash": "fae889d383b38e54604c1720fb123275"
            },
            {
              "url": "",
              "title": "Natera, Inc. v. NeoGenomics Laboratories, Inc., No. 24-1324 (Fed. Cir ...",
              "snippet": "Natera, Inc. and NeoGenomics Laboratories, Inc. are healthcare companies in the oncology testing industry. Natera owns two patents, U.S. Patent No. 11,519,035 and U.S. Patent No. 11,530,454, which cover methods for amplifying and sequencing DNA to detect cancer relapse. Natera uses these methods in its Signatera product, while NeoGenomics offers a competing product called RaDaR. Natera sued ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650004+00:00",
              "published_date": null,
              "source_hash": "c837b1d4818540edff04d68a3b74207b"
            },
            {
              "url": "",
              "title": "Jury Rules in Favor of Natera, Finding all Asserted Patents Valid and ...",
              "snippet": "AUSTIN, Texas-(BUSINESS WIRE)- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in the patent infringement suit it filed against ArcherDX/Invitae Corp. The jury found that all accused ArcherDX/Invitae products infringe three of Natera ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650016+00:00",
              "published_date": null,
              "source_hash": "1bb378df56227837919d75acb9d5d418"
            },
            {
              "url": "",
              "title": "Court Grants Natera's Request to Include Additional Patent in its ...",
              "snippet": "AUSTIN, Texas, December 17, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650026+00:00",
              "published_date": null,
              "source_hash": "56d484aa84de3be32a4e7a4dfb512a22"
            },
            {
              "url": "",
              "title": "Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against ...",
              "snippet": "AUSTIN, Texas-(BUSINESS WIRE)- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement case against CareDx, Inc. The jury awarded Natera $83.7 million in lost profits and $12.6 million in past royalties after ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650037+00:00",
              "published_date": null,
              "source_hash": "853cb65fcbee134159b5b548ed141bc6"
            },
            {
              "url": "",
              "title": "Natera, Inc. | Jury Rules in Favor of Natera in Patent Infringement ...",
              "snippet": "AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of Natera in its patent infringement case against CareDx, Inc. The jury awarded Natera $83.7 million in lost profits and $12.6 million in past royalties after finding ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650048+00:00",
              "published_date": null,
              "source_hash": "37f798e3387735799deb1d383ae9f611"
            },
            {
              "url": "",
              "title": "Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against ...",
              "snippet": "AUSTIN, Texas, January 29, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that a jury in the U.S. District Court for the District of Delaware has ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650057+00:00",
              "published_date": null,
              "source_hash": "7969d219ef081e590b35c2526cdcb59c"
            },
            {
              "url": "",
              "title": "Natera, Inc. | Court Orders Permanent Injunction Against NeoGenomics ...",
              "snippet": "Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today issued the following statement regarding its ongoing patent infringement litigation with NeoGenomics in response to inquiries: On Sept. 23, 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics accused RaDaR assay, which was ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941666+00:00",
              "published_date": null,
              "source_hash": "c06438d626167e05aafc11bc3b1dafb8"
            },
            {
              "url": "",
              "title": "Natera: Poised For A Great Future But I'd Wait For A Pullback",
              "snippet": "This commenced in 2019 when CareDx filed a patent infringement lawsuit against Natera that ended with the judge dismissing the former's patents and invalidating their exclusive rights to the cfDNA ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:06.650075+00:00",
              "published_date": null,
              "source_hash": "fd7459c2b9658271808789e70014db5b"
            },
            {
              "url": "",
              "title": "Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics",
              "snippet": "AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:09.248522+00:00",
              "published_date": "2024-12-17T08:00:00+00:00",
              "source_hash": "bb6613ae7b94b9e4e8258e0a90681d0c"
            },
            {
              "url": "",
              "title": "Natera: Poised For A Great Future But I'd Wait For A Pullback",
              "snippet": "Natera, a leader in cfDNA testing, has shown impressive growth and is nearing profitability, but its current valuation appears overextended. Read more here.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:09.248621+00:00",
              "published_date": "2024-12-31T09:50:00+00:00",
              "source_hash": "3be133faf0ed2b1e49c686986c9a60c4"
            },
            {
              "url": "",
              "title": "Natera expands patent infringement lawsuit against NeoGenomics",
              "snippet": "Natera (NTRA) announced an expansion of its patent infringement lawsuit against NeoGenomics (NEO) related to its RaDaR tests. On December 10, the District Court for the Middle District of North ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:09.248649+00:00",
              "published_date": "2024-12-17T13:10:00+00:00",
              "source_hash": "91e7c87aaacb154f3f7d114e4874d4b2"
            },
            {
              "url": "",
              "title": "CareDX pares loss, gains after jury awards $96M to Natera in patent dispute (update)",
              "snippet": "CareDX (NASDAQ:CDNA) pared an earlier loss and gained 8% after a jury awarded $96.3 million to Natera (NASDAQ:NTRA) in a patent dispute ... Natera in a separate lawsuit. The invalidity of CareDx ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:09.248674+00:00",
              "published_date": "2024-01-29T16:42:00+00:00",
              "source_hash": "c1d3e226ba2f454933776d7b5b77be38"
            },
            {
              "url": "",
              "title": "Natera expands lawsuit against NeoGenomics over RaDaR test",
              "snippet": "AUSTIN, Texas - Natera, Inc. (NASDAQ ... has broadened its patent infringement litigation against NeoGenomics (NASDAQ:NEO), Inc., involving the RaDaR assay, a test for molecular residual disease.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Natera Inc Natera Inc patent disputes litigation",
              "retrieved_at": "2025-01-06T14:50:09.248696+00:00",
              "published_date": "2024-12-17T08:05:00+00:00",
              "source_hash": "555b339cc3bb3bc495c33fa10b8a6f29"
            },
            {
              "url": "",
              "title": "Notice of Privacy Practices - Natera",
              "snippet": "Natera's notice of privacy practices. This notice describes how medical information about you may be disclosed and how you can get access to this information. ... to disclose that information. Examples include information dealing with matters such as genetic testing, HIV/AIDS, mental health (including psychotherapy notes), alcohol and substance ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941542+00:00",
              "published_date": null,
              "source_hash": "1d4b23c01e82826ebdb33a60122fcf15"
            },
            {
              "url": "",
              "title": "Privacy Policy - Natera",
              "snippet": "Women's Health. TESTS. Horizon - Advanced Carrier Screening; Panorama - Noninvasive Prenatal Testing (NIPT); Empower - Hereditary Cancer Test; Vistara - Single-Gene NIPT; Anora - Miscarriage Test; Vasistera - Limited Noninvasive Prenatal Testing (NIPT); Spectrum - Preimplantation Genetics; FOR PATIENTS. Pricing and Billing Information; Women's Health Portal ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941614+00:00",
              "published_date": null,
              "source_hash": "de25e1d5d8d11e3374235a6fc123c218"
            },
            {
              "url": "",
              "title": "Natera Investors Partly Advance Suit Over Genetic Tests (1)",
              "snippet": "Natera Inc. and its leadership must face allegations that they misrepresented the efficacy of certain genetic tests, as well as sales and billing practices the diagnostics company used, a judge said. Judge David Ezra found that the Natera shareholders sufficiently stated actionable omissions and plead loss causation stemming from the alleged misrepresentations' impact on share prices, citing ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941656+00:00",
              "published_date": null,
              "source_hash": "5486a86676801138fc6faaef5f38d98f"
            },
            {
              "url": "",
              "title": "CareDx owes Natera $96 mln in genetic-testing patent case, US jury says",
              "snippet": "A jury in Delaware federal court has awarded genetic-testing company Natera more than $96.3 million in damages after finding that rival CareDx's AlloSure and AlloSeq kidney-transplant tests ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941676+00:00",
              "published_date": null,
              "source_hash": "97639bef7dd4054427e2adb34dda7f70"
            },
            {
              "url": "",
              "title": "Natera Facing Investor Class Action Over Genetic Test Accuracy Concerns",
              "snippet": "The Times reported, among other things, that the positive test results for certain genetic disorders given by Natera's tests were incorrect more than 80 percent of the time, the suit states. Upon this news, Natera's stock price fell by $5.35 per share, or roughly six percent, to close at $88.04 per share on January 4, the complaint says.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941686+00:00",
              "published_date": null,
              "source_hash": "baf68173c8b357827cf607313ae42e4d"
            },
            {
              "url": "",
              "title": "Class Action Alleges Customers Received Surprise Bills for Natera ...",
              "snippet": "Natera, Inc. faces a proposed class action that claims the genetic testing company has misrepresented the costs of its tests and hit thousands of patients with unexpected, \"extremely high\" bills. ... Natera markets its genetic tests, including carrier screening tests and pre-natal genetic tests, to women who are trying to conceive and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941704+00:00",
              "published_date": null,
              "source_hash": "d13f6f5fcaee5924a54ae5d0bc05017c"
            },
            {
              "url": "",
              "title": "CareDx owes Natera $96 mln in genetic-testing patent case, US ... - Nasdaq",
              "snippet": "Jan 29 (Reuters) - A jury in Delaware federal court has awarded genetic-testing company Natera NTRA.O more than $96.3 million in damages after finding that rival CareDx's CDNA.O AlloSure and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:10.941713+00:00",
              "published_date": null,
              "source_hash": "06d7f053def62d5f40d513b94b64253e"
            },
            {
              "url": "",
              "title": "Natera Issues Statement on Guardant Health Litigation",
              "snippet": "Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today issued the following statement: In 2021, Natera and Guardant Health filed false advertising cases against each other concerning statements both companies made more ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:13.273715+00:00",
              "published_date": "2024-11-25T00:00:00+00:00",
              "source_hash": "48bd94e2dd69247d61436ef6db9e4a0b"
            },
            {
              "url": "",
              "title": "What Makes Natera (NTRA) a Top Stock Pick for Billionaire Stanley Druckenmiller?",
              "snippet": "In addition to inflationary concerns ... regarding Natera, Inc. (NASDAQ:NTRA) in its Q3 2024 investor letter: \"Natera, Inc. (NASDAQ:NTRA) is a specialty lab providing genetic testing services ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:13.273820+00:00",
              "published_date": "2024-12-17T12:07:00+00:00",
              "source_hash": "00647ca64bc6107cce210baa216ba4a5"
            },
            {
              "url": "",
              "title": "Natera, Inc. (NTRA)",
              "snippet": "AUSTIN, Texas, November 26, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present new SignateraTM data at the San Antonio ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:13.273846+00:00",
              "published_date": "2025-01-04T00:00:00+00:00",
              "source_hash": "d6010b575e787f14f562f85ea5ba5191"
            },
            {
              "url": "",
              "title": "What the Options Market Tells Us About Natera",
              "snippet": "Natera Option Volume And Open Interest Over Last 30 Days Natera Inc ... genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:13.273860+00:00",
              "published_date": "2024-11-11T15:30:00+00:00",
              "source_hash": "b85ab97393e3c50a0e6a7ff6b2dd97c6"
            },
            {
              "url": "",
              "title": "Natera expands lawsuit against NeoGenomics over RaDaR test",
              "snippet": "AUSTIN, Texas - Natera, Inc ... genetic testing into standard care to enhance early and targeted interventions for better health outcomes. According to InvestingPro data, Natera demonstrates ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Natera Inc Natera Inc data privacy concerns genetic testing",
              "retrieved_at": "2025-01-06T14:50:13.273870+00:00",
              "published_date": "2024-12-17T08:05:00+00:00",
              "source_hash": "9ed0fc547ea6b6fff209b3c79c055e64"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Natera Inc reimbursement challenges insurance",
              "rationale": "Investigate ongoing issues with insurance reimbursement rates impacting revenue",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Natera Inc patent disputes litigation",
              "rationale": "Explore legal challenges and patent disputes affecting the company",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Natera Inc data privacy concerns genetic testing",
              "rationale": "Examine concerns related to patient privacy and data security in handling genetic data",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T07:50:32.760549",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}